51. Placental Passage of Humulone and Protopine in an Ex Vivo Human Perfusion System
- Author
-
Elisa Duong, Andrea Treyer, Ana Paula Simões-Wüst, Michael Reinehr, Vanessa Fabienne Abegg, Mouhssin Oufir, Deborah Spiess, Antoine Chauveau, Matthias Hamburger, and Olivier Potterat
- Subjects
medicine.drug_class ,Placenta ,Berberine Alkaloids ,Pharmaceutical Science ,In Vitro Techniques ,030226 pharmacology & pharmacy ,Analytical Chemistry ,Andrology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pregnancy ,Tandem Mass Spectrometry ,Drug Discovery ,Cyclohexenes ,medicine ,Humans ,Humulone ,Maternal-Fetal Exchange ,030304 developmental biology ,Pharmacology ,Benzophenanthridines ,0303 health sciences ,Fetus ,Chemistry ,Terpenes ,Leptin ,Organic Chemistry ,3. Good health ,Perfusion ,medicine.anatomical_structure ,Complementary and alternative medicine ,Molecular Medicine ,Protopine ,Gonadotropin ,Ex vivo - Abstract
The placental passage of humulone and protopine was investigated with a human ex vivo placental perfusion model. The model was first validated with diazepam and citalopram, 2 compounds known to cross the placental barrier, and antipyrine as a positive control. All compounds were quantified by partially validated U(H)PLC-MS/MS bioanalytical methods. Only a small portion of humulone initially present in the maternal circuit reached the fetal circuit. The humulone concentration in the maternal circuit rapidly decreased, likely due to metabolization in the placenta. Protopine was transferred from the maternal to the fetal circuit, with a steady-state reached after 90 min. None of the study compounds affected placental viability or functionality, as glucose consumption, lactate production, beta-human chorionic gonadotropin, and leptin release remained constant. Histopathological evaluation of all placental specimens showed unremarkable, age-appropriate parenchymal maturation with no pathologic findings.
- Published
- 2021